DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Thursday. The firm issued a hold rating on the stock.

A number of other research firms also recently commented on DBVT. HC Wainwright raised their price objective on DBV Technologies from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Price Performance

Shares of DBVT stock opened at $0.59 on Thursday. The firm’s 50-day simple moving average is $0.72 and its 200-day simple moving average is $0.89. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $2.14. The firm has a market cap of $56.92 million, a P/E ratio of -0.66 and a beta of 0.66.

DBV Technologies shares are set to reverse split on the morning of Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 28th.

Institutional Inflows and Outflows

A hedge fund recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. increased its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies comprises 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.